Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Publication information:
Iavarone C, Zervantonakis I, Selfors L, Palakurthi S, Liu J, Drapkin R, Matulonis U, Hallberg D, Velculescu V, Leverson J, Sampath D, Mills G, Brugge J. Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.
Mol Cancer Ther. 2019;18(3):642–655.